Patients with autoimmune systemic diseases (ASD) are less likely to produce an immune response following inoculation with mRNA vaccines against the coronavirus disease 2019 (COVID-19), according to a recent study.
Switching to tenofovir alafenamide (TAF) from nucleos(t)ide analogue therapies was associated with improved virologic response and liver function in patients with chronic hepatitis B virus (HBV) infection, even in those with decompensated HBV cirrhosis, according to real-world studies presented at AASLD 2021.
Despite the uptick in digital cardiology care during the coronavirus disease 2019 (COVID-19) pandemic, several key barriers to wearable device use remain, including high costs and limited technology knowledge, according to a recent study.
The pleuromutilin inhibitor lefamulin shows similarly high efficacy as moxifloxacin (a standard fluoroquinolone therapy for clearing bacterial pneumonia) regardless of whether it was for unilobar or multilobar pneumonia, according to pooled data of the LEAP* 1 and 2 studies.
Child abuse rates appear to have increased during the lockdowns imposed to control COVID-19 transmission, according to a study from the US presented at the 2021 American Academy of Pediatrics National Conference & Exhibition (AAP 2021).
The oral antiviral drug umifenovir, which is used to treat influenza, appears to be beneficial in COVID-19 patients who are asymptomatic or with mild symptoms, with a phase III study showing that the drug is well tolerated and can induce viral clearance within 5 days.
A recent Singapore meta-analysis of randomized controlled trials (RCT) has found no clear clinical benefit to using convalescent plasma (CP) for patients with the coronavirus disease 2019 (COVID-19), especially in those with severe disease.